Trial Profile
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Clopidogrel (Primary) ; Prasugrel (Primary)
- Indications Acute coronary syndromes; Thromboembolism
- Focus Pharmacodynamics
- Acronyms TEGCOR
- 20 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.
- 20 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Dec 2016.
- 04 Apr 2016 Status changed from recruiting to discontinued due to slow enrolment as reported by ClinicalTrials.gov.